Mesoblast Ltd

MSB

Company Profile

  • Business description

    Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

  • Contact

    55 Collins Street
    Level 38
    MelbourneVIC3000
    AUS

    T: +61 396396036

    E: [email protected]

    https://www.mesoblast.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    73

Mesoblast Ltd News & Analysis

stocks

Shorts circle BHP ahead of listing unification: ASX’s most shorted stocks

Morningstar analysts see value in several stocks under fire from shorts.
stocks

Mayne Pharma woes to persist for 2020

Morningstar had forecast big losses for the drugmaker, which has been dropped from the ASX 200.
stocks

CSL remains favourite, but biotech field broadening

The biotech giant has jumped 22pc a year for the past decade but new players are emerging.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,515.203.70-0.04%
CAC 407,226.98199.90-2.69%
DAX 4019,033.64414.96-2.13%
Dow JONES (US)43,910.98382.15-0.86%
FTSE 1008,025.7799.42-1.22%
HKSE19,846.88580.05-2.84%
NASDAQ19,281.4017.36-0.09%
Nikkei 22539,376.09157.23-0.40%
NZX 50 Index12,684.5664.80-0.51%
S&P 5005,983.9917.36-0.29%
S&P/ASX 2008,255.6010.60-0.13%
SSE Composite Index3,421.9748.10-1.39%

Market Movers